Cited by 173Sepsis Diagnosis and TreatmentImmune Response and InflammationInflammation biomarkers and pathways

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

Open access

Barochia, Amisha, Solomon, Steven, Cui, Xizhong, Natanson, Charles, Eichacker, Peter Q·2011·Expert Opinion on Drug Metabolism & Toxicology

DOI 10.1517/17425255.2011.558190PMC PMC3065179

Open this paper in CoChat — free account

Abstract

INTRODUCTION: Sepsis remains a leading cause of death worldwide. Despite years of extensive research, effective drugs that inhibit the pro-inflammatory effects of lipopolysaccharide (LPS) and improve outcome when added to conventional sepsis treatments are lacking. Eritoran tetrasodium (E5564) is a promising candidate therapy for sepsis belonging to a new class of such drugs which inhibit LPS-induced inflammation by blocking toll-like receptor 4. AREAS COVERED: This review focuses on the rationale for the use of eritoran tetrasodium in sepsis as well as on its pharmacokinetics, pharmacodynamics, efficacy and safety. Preclinical and clinical studies from a MEDLINE/PubMed literature search in August 2010 with the search terms 'eritoran' and 'E5564' are discussed. EXPERT OPINION: Preclinical in vitro and in vivo studies of eritoran tetrasodium indicate it can limit excessive inflammatory mediator release associated with LPS and improve survival in sepsis models. While early clinical results are promising, its efficacy and safety for treating patients with sepsis are currently under investigation. Even if the ongoing Phase III clinical trial enrolling patients with severe sepsis and increased risk of death shows benefit from eritoran, questions remain and confirmatory studies would be necessary to define its clinical usage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1517/17425255.2011.558190

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Innate immune recognition
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Bernard, G. R., Vincent, J., Laterre, P., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,124
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777
Toll-like receptors in the induction of the innate immune response
Aderem, A. A., & Ulevitch, R. J. (2000) · Nature · doi:10.1038/35021228 · Cited by 3,082
The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex
Park, B. S., Song, D. H., Kim, H. M., Choi, B., Lee, H., & Lee, J. (2009) · Nature · doi:10.1038/nature07830 · Cited by 2,513
Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin
Ziegler, E. J., Fisher, C. J., Sprung, C. L., Straube, R., SADOFF, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240701 · Cited by 1,618
Bacterial endotoxin: molecular relationships of structure to activity and function
Rietschel, E., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A. J., Zähringer, U., Seydel, U., Padova, F. D., et al. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.2.8119492 · Cited by 1,608
High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes
Andersson, U., Wang, H., Palmblad, K., Aveberger, A.-C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.565 · Cited by 1,401
Bacterial lipopolysaccharides and innate immunity
Alexander, C., & Rietschel, E. T. (2001) · Journal of Endotoxin Research · doi:10.1179/096805101101532675 · Cited by 1,206
Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran
Kim, H. M., Park, B. S., Kim, J.-I., Kim, S. E., Lee, J., Oh, S. C., Enkhbayar, P., Matsushima, N., Lee, H., Yoo, O. J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.002 · Cited by 1,180
Recognition of pathogen-associated molecular patterns by TLR family
Akira, S., & Hemmi, H. (2003) · Immunology Letters · doi:10.1016/s0165-2478(02)00228-6 · Cited by 1,162
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
Abraham, E. H., Laterre, P., Garg, R., Levy, H. A., Talwar, D., Trzaskoma, B. L., François, B., Guy, J. S., Brückmann, M., Réa-Neto, Á., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050935 · Cited by 887
Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial
Fisher, C. J. (1994) · JAMA · doi:10.1001/jama.1994.03510470040032 · Cited by 790
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
Opal, S. M., Scannon, P. J., Vincent, J., White, M., Carroll, S. F., Palardy, J. E., Parejo, N. A., Pribble, J. P., & Lemke, J. H. (1999) · The Journal of Infectious Diseases · doi:10.1086/315093 · Cited by 609
Human Toll‐Like Receptor 4 Mutations but Not CD14 Polymorphisms Are Associated with an Increased Risk of Gram‐Negative Infections
Agnese, D. M., Calvano, J. E., Hahm, S. J., Coyle, S. M., Corbett, S., Calvano, S. E., & Lowry, S. F. (2002) · The Journal of Infectious Diseases · doi:10.1086/344893 · Cited by 580
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
Rice, T. W., Wheeler, A. P., Bernard, G. R., Vincent, J.-L., Angus, D. C., Aikawa, N., Demeyer, I., Sainati, S., Amlot, N., Cao, C., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e7c5c9 · Cited by 512
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*
Panacek, E. A., Marshall, J. C., Albertson, T. E., Johnson, D. H., Johnson, S. B., MacArthur, R. D., Miller, M. J., Barchuk, W., Fischkoff, S. A., Kaul, M., et al. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000145229.59014.6c · Cited by 393
p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock
Abraham, E. H. (1997) · JAMA · doi:10.1001/jama.1997.03540430043031 · Cited by 377
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin
Bone, R. C., BALK, R. A., Fein, A. M., Perl, T. M., Wenzel, R. P., Reines, H. D., Quenzer, R. W., Iberti, T. J., MacIntyre, N. R., & Schein, R. M. H. (1995) · Critical Care Medicine · doi:10.1097/00003246-199506000-00003 · Cited by 347
Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis
Eichacker, P. Q., Parent, C., Kalil, A. C., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., & Natanson, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-302oc · Cited by 340
Self-citation
Identification of pediatric septic shock subclasses based on genome-wide expression profiling
Wong, H. R., Cvijanovich, N. Z., Lin, R., Allen, G. L., Thomas, N. J., Willson, D. F., Freishtat, R. J., ANAS, N. G., Meyer, K., Checchia, P. A., et al. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-34 · Cited by 309
Inhibition of Endotoxin Response by E5564, a Novel Toll-Like Receptor 4-Directed Endotoxin Antagonist
Mullarkey, M. A., Rose, J., Bristol, J., Kawata, T., Kimura, A., Kobayashi, S., Przetak, M. M., Chow, J. C., Gusovsky, F., Christ, W. J., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044487 · Cited by 292
Inhibition of Toll-like Receptor 4 With Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury
Shimamoto, A., Chong, A. J., Yada, M., Shomura, S., Takayama, H., Fleisig, A. J., Agnew, M. L., Hampton, C. R., Rothnie, C. L., Spring, D. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.000901 · Cited by 283
Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4
Roger, T., Froidevaux, C., Roy, D. L., Reymond, M. K., Chanson, A.-L., Mauri, D., Burns, K., Riederer, B. M., Akira, S., & Calandra, T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808146106 · Cited by 267
E5 Murine Monoclonal Antiendotoxin Antibody in Gram-Negative Sepsis A Randomized Controlled Trial
Angus, D. C. (2000) · JAMA · doi:10.1001/jama.283.13.1723 · Cited by 266
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*
Tidswell, M., Tillis, W. P., LaRosa, S. P., Lynn, M., Wittek, A. E., Kao, R., Wheeler, J. L., Gogate, J. P., & Opal, S. M. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b07b78 · Cited by 233
Pharmacological Inhibition of Endotoxin Responses Is Achieved by Targeting the TLR4 Coreceptor, MD-2
Visintin, A., Halmen, K. A., Latz, E., Monks, B. G., & Golenbock, D. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.6465 · Cited by 153
Blocking of Responses to Endotoxin by E5564 in Healthy Volunteers with Experimental Endotoxemia
Lynn, M., Rossignol, D. P., Wheeler, J. L., Kao, R., Perdomo, C. A., Noveck, R. J., Vargas, R., D’Angelo, T., Gotzkowsky, S., & McMahon, F. G. (2003) · The Journal of Infectious Diseases · doi:10.1086/367990 · Cited by 150
Anti-inflammatory therapies in sepsis and septic shock
Freeman, B. D., & Natanson, C. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.7.1651 · Cited by 146
Self-citation
Toll-like Receptor 4 Modulation as a Strategy to Treat Sepsis
Wittebole, X., Castanares‐Zapatero, D., & Laterre, P. (2010) · Mediators of Inflammation · doi:10.1155/2010/568396 · Cited by 141
The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis
Minneci, P. C., Deans, K. J., Eichacker, P. Q., & Natanson, C. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02752.x · Cited by 132
Self-citation
Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome
Child, N. J. A., Yang, I. A., Pulletz, M., de Courcy-Golder, K., ANDREWS, A., Pappachan, J., & Holloway, J. W. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310652 · Cited by 98
Inhibition of Endotoxin Response by Synthetic TLR4 Antagonists
Hawkins, L. D., Christ, W. J., & Rossignol, D. P. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043388123 · Cited by 89
CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)*
Reinhart, K., Glück, T., Ligtenberg, J. J. M., Tschaikowsky, K., Bruining, A., Bakker, J., Opal, S. M., Moldawer, L. L., Axtelle, T., Turner, T., et al. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000124870.42312.c4 · Cited by 80
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue
Rossignol, D. P., & Lynn, M. (2002) · Journal of Endotoxin Research · doi:10.1179/096805102125001127 · Cited by 77
Physiologic, Biochemical, and Imaging Characterization of Acute Lung Injury in Mice
Zhou, Z., KOZLOWSKI, J. K., & Schuster, D. P. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200503-343oc · Cited by 75
Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide
Savov, J. D., Brass, D. M., Lawson, B. L., McElvania, E., Walker, J. K. L., & Schwartz, D. A. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00014.2005 · Cited by 73
TLR4 antagonists for endotoxemia and beyond.
Rossignol, D. P., & Lynn, M. (2005) · PubMed · Cited by 72
Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers
Rossignol, D. P., Wasan, K. M., Choo, E., Yau, E. H., Wong, N., Rose, J., Moran, J., & Lynn, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3233-3240.2004 · Cited by 72
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue
Rossignol, D. P., & Lynn, M. (2002) · Journal of Endotoxin Research · doi:10.1177/09680519020080060601 · Cited by 70
A Phase II, Double-Blind, Placebo-Controlled, Ascending-Dose Study of Eritoran (E5564), a Lipid A Antagonist, in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass
Bennett‐Guerrero, E., Grocott, H. P., Levy, J. H., Stierer, K. A., Hogue, C. W. J., Cheung, A. T., Newman, M. F., Carter, A. A., Rossignol, D. P., & Collard, C. D. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000253501.07183.2a · Cited by 67
Protective Effects of Toll-like Receptor 4 Inhibitor Eritoran on Renal Ischemia-Reperfusion Injury
Liu, M., Gu, M., Xu, D., Lv, Q., Zhang, W., & Wu, Y. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.03.133 · Cited by 63
Safety, Pharmacokinetics, and Pharmacodynamics of E5564, a Lipid A Antagonist, during an Ascending Single‐Dose Clinical Study
Wong, Y. N., Rossignol, D. P., Rose, J., Kao, R., Carter, A. R., & Lynn, M. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003254804 · Cited by 54
Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients
Harkonen, S., Scannon, P. J., Mischak, R. P., S̄pitler, L. E., Foxall, C., Kennedy, D., & Greenberg, R. N. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.5.710 · Cited by 51
Novel therapies for sepsis: antiendotoxin therapies
Manocha, S., Feinstein, D., Kumar, A., & Kumar, A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1795 · Cited by 49
Once is not enough: clinical trials in sepsis
Sweeney, D. A., Danner, R. L., Eichacker, P. Q., & Natanson, C. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1274-6 · Cited by 46
Self-citation
Inhibition of Corneal Inflammation by the TLR4 Antagonist Eritoran Tetrasodium (E5564)
Sun, Y., & Pearlman, E. M. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2628 · Cited by 43
Salvage effect of E5564, Toll‐like receptor 4 antagonist on d‐galactosamine and lipopolysaccharide‐induced acute liver failure in rats
Kitazawa, T., Tsujimoto, T., Kawaratani, H., & Fukui, H. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06145.x · Cited by 40
Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin
Golenbock, D. T., Will, J. A., Raetz, C. R., & Proctor, R. A. (1987) · Infection and Immunity · doi:10.1128/iai.55.10.2471-2476.1987 · Cited by 39
Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, Gram-negative sepsis
Greenberg, R. N., Wilson, K., Kunz, A. Y., Wedel, N. I., & Gorelick, K. J. (1992) · Critical Care Medicine · doi:10.1097/00003246-199206000-00005 · Cited by 37
Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia
Lynn, M., Wong, Y. N., Wheeler, J. L., Kao, R., Perdomo, C. A., Noveck, R. J., Vargas, R., D’Angelo, T., Gotzkowsky, S., McMahon, F. G., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.056531 · Cited by 36
Cachectin/TNF mediates the pathophysiological effects of bacterial endotoxin/lipopolysaccharide (LPS).
Tracey, K. J., Sf, L., & Cerami, A. (1988) · PubMed · Cited by 35
Therapeutic approach to regulate innate immune response by Toll‐like receptor 4 antagonist E5564 in rats with D‐galactosamine‐induced acute severe liver injury
Kitazawa, T., Tsujimoto, T., Kawaratani, H., & Fukui, H. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05770.x · Cited by 33
Lipid X protects mice against fatal Escherichia coli infection
Golenbock, D. T., Leggett, J. E., Rasmussen, P., Craig, W. A., Raetz, C. R. H., & Proctor, R. A. (1988) · Infection and Immunity · doi:10.1128/iai.56.4.779-784.1988 · Cited by 32
Effective Dosing of Lipid A Analogue E5564 in Rats Depends on the Timing of Treatment and the Route ofEscherichia coliInfection
Solomon, S. B., Cui, X., Gerstenberger, E. P., Danner, R. L., Fitz, Y., Banks, S. M., Natanson, C., & Eichacker, P. Q. (2006) · The Journal of Infectious Diseases · doi:10.1086/500147 · Cited by 29
Self-citation
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers
Rossignol, D. P., Wong, N., Noveck, R. J., & Lynn, M. (2008) · Innate Immunity · doi:10.1177/1753425908099173 · Cited by 24
Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations
Wasan, K. M., Sivak, O., Cote, R. A., MacInnes, A. I., Boulanger, K. D., Lynn, M., Christ, W. J., Hawkins, L. D., & Rossignol, D. P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2796-2803.2003 · Cited by 14
Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis*
Barochia, A. V., Cui, X., Natanson, C., & Eichacker, P. Q. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b77fe3 · Cited by 12
Self-citation
Activation of TLR4/NF-κB signaling pathway in early brain injury after subarachnoid hemorrhage
Ma, C., Yin, W.-N., Cai, B., He, M., Wu, J., Wang, J., Zeng, Y., Ding, J., & You, C. (2009) · Neurological Research · doi:10.1179/016164109x12445616596283 · Cited by 11
Quantitative determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by high-performance liquid chromatography with fluorescence detection
Kaneko, K., Ueda, R., Kikuchi, K., Sano, Y., & Yoshimura, T. (1999) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(99)00438-7 · Cited by 10
Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function
Liang, E., Wong, Y. N., Allen, I. E., Kao, R., Marino, M. T., & DiLea, C. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003258653 · Cited by 10
Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits
Wasan, K. M., Risovic, V., Sivak, O., Lee, S. D., Mason, D. X., Chiklis, G. R., McShane, J., Lynn, M., Wong, N., & Rossignol, D. P. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9428-8 · Cited by 8
LPS binding protein does not participate in the pharmacokinetics of E5564
Kaneko, K., Ueda, R., Kawata, T., Ishizaka, S. T., & Yoshimura, T. (2004) · Journal of Endotoxin Research · doi:10.1177/09680519040100030501 · Cited by 7
Disposition of a synthetic analogue of lipid A (E5564) in rats
Kaneko, K., Ueda, R., Nemoto, H., Iijima, H., & Yoshimura, T. (2003) · Xenobiotica · doi:10.1080/0049825021000058097 · Cited by 7
Drug evaluation: E-5564.
Ondiveeran, H. K., & Fox‐Robichaud, A. (2004) · PubMed · Cited by 7

Flagged first, then by citations

Research works printed but not linked: 7

Tracey KJ, 1988, Prog Clin Biol Res, 272, 77
Alexander C, 2001, J Endotoxin Res, 7, 167
Shimamoto A, 2006, Circulation, 114, I270
Ondiveeran HK, 2004, IDrugs, 7, 582
10.1086/315093 · DOI · Paper page
Rossignol DP, 2005, Curr Opin Investig Drugs, 6, 496
Suganuma A, 2000, J Endotoxin Res, 6, 115

Sorted by citations

Recognition of lipopolysaccharide pattern by TLR4 complexes
Park, B. S., & Lee, J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.97 · Cited by 1,276
The Gut Microbiome, Kidney Disease, and Targeted Interventions
Ramezani, A., & Raj, D. S. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013080905 · Cited by 773
TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis
Kuzmich, N. N., Сивак, К. В., Chubarev, V. N., Porozov, Y. B., Savateeva-Lyubimova, T. N., & Peri, F. (2017) · Vaccines · doi:10.3390/vaccines5040034 · Cited by 665
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Toll-like receptors activation, signaling, and targeting: an overview
El-Zayat, S. R., Sibaii, H., & Mannaa, F. A. E. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0227-2 · Cited by 603

See all 173

Authors: Barochia, A., Solomon, S., Cui, X., Natanson, C., & Eichacker, P. Q.
Affiliations: National Institutes of Health (US)
ORCID: Barochia, Amisha
Solomon, Steven
Natanson, Charles
Eichacker, Peter Q
Venue: Expert Opinion on Drug Metabolism & Toxicology
Publisher: Informa Healthcare
Published: 2011-02-17
Volume: 7
Issue: 4
Pages: 479-494
ISSN: 1742-5255 (ISSN-L)
1744-7607
DOI: 10.1517/17425255.2011.558190
PMC: PMC3065179
OpenAlex: W2161681729
Cited by: 169
References: 66
Citations by year: 2026: 5 · 2025: 15 · 2024: 9 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 12 · 2019: 12 · 2018: 12 · 2017: 13 · 2016: 12 · 2015: 8 · 2014: 10 · 2013: 14 · 2012: 13
FWCI: 10.26
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Expert Opinion on Drug Metabolism & Toxicology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99CL999999)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords: sepsis, lipopolysaccharide, TLR4, anti-inflammatory therapy, pharmacokinetics, pharmacodynamics, drug safety, sepsis mortality, inflammatory mediator release
MeSH terms: Animals, Anti-Inflammatory Agents, Clinical Trials as Topic, Disaccharides, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Humans, Lipopolysaccharides, Sugar Phosphates, Sepsis, Toll-Like Receptor 4, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks